Current Clinical Trials

Multiple Myeloma

CAR-T:

  • A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of bb2121 versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) (NCT03651128)
  • A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma (CARTITUDE-2) (NCT04133636)

BiTES

  • A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma (NCT03933735)

NK Cells:

  • A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma (NCT04614636)
  • A Pilot Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML after Allogeneic Hematopoietic Cell Transplant in Children and Young Adults (NCT03068819)

Acute Myeloid Leukemia (AML)

CAR-T

  • A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (NCT04789408)

NK Cells:

  • A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation (NCT02782546) 
  • A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma (NCT04614636)
  • A Pilot Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML after Allogeneic Hematopoietic Cell Transplant in Children and Young Adults (NCT03068819)  

Myelodysplastic Syndromes (MDS)

None currently listed

Chronic Lymphocytic Leukemia (CLL)

CAR-T:

  • A Phase 1/2 MulticenteAn Open-Label, Multicenter, Phase I/Ib trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined with Atezolizumab in patients with Relapsed or Refractory B-Cell Non-Hodgkin s Lymphoma and Chronic Lymphocytic Leukemia (NCT02500407)

CAR-NK:

  • A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination with Rituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia (NCT04245722)

Acute Lymphoblastic Leukemia (ALL)

CAR-T:

  • A phase II study of inotuzumab ozogamicin followed by blinatumomab for Ph-negative, CD22-positive B-lineage acute lymphoblastic leukemia in newly diagnosed older adults or adults with relapsed or refractory disease (NCT03739814)
  • A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART -007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL) (NCT04984356)
  • A Phase 2, Single-Arm, Open-Label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy (NCT04071366)
  • An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating The Safety And Efficacy Of AUTO1, A CAR-T Cell Treatment Targeting CD19, In Adult Patients With Relapsed Or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (NCT04404660)
  • A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies (NCT04035434)

T-cell Lymphoblastic Lymphoma (T-LBL)

CAR-T

  • A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies (NCT04035434)

Post-Transplant Lymphoproliferative Disorder (PTLD) & Epstein-Barr Virus (EBV) Malignancies

Viral Cytotoxic Lymphocytes:

  • Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) (NCT03394365)  
  • An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases (NCT04554914)

Lymphoma

CAR-T:

  • A Phase 2, Single-Arm, Open-Label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy (NCT04071366)  
  • A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies (NCT04035434)
  • A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (efineptakin alfa) a Long-acting Human IL-7, post-Tisagenlecleuel (Kymriah®) in Subjects with Relapsed/Refractory Large B-cell Lymphoma (NCT04831320)

BiTES:

  • An Open-Label, Multicenter, Phase I/Ib trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined with Atezolizumab in patients with Relapsed or Refractory B-Cell Non-Hodgkin s Lymphoma and Chronic Lymphocytic Leukemia (NCT02500407)
  • A Multicenter, Open-Label, Phase I Study To Evaluate the Safety, Efficacy,Tolerability and Pharmacokinetics Of Escalating Doses OF RO7082859 As A Single Agent and in Combination With Obinutuzumab Administered After A Fixed, Single Dose Pre-Treatment of Obinutuzumab (Gazyva/Gazyvaro) in Patients With Relapsed/Refractory B-Cell Non-Hodgkins Lymphoma (NCT03075696)

Solid Tumors

CAR-T:

  • A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma (NCT04025216)

TCR Modified T Cells:

  • A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD 1 STUDY) (NCT04044768)   
  • A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (NCT04044859)
  • Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (NCT03967223)
  • Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, alone or in combination with other agents, in Participants with Advanced Tumors (NCT04526509)
  • A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer (NCT03319940)
  • A Phase 2 Open-Label clinical trial of ADP-A2M4CD8 in subjects with advanced esophageal or esophagogastric junction cancers (surpass-2 study) (NCT04752358)

BiTEs, DARTs, and Tetravalent Bispecifics:

  • A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy (NCT03872206)
  • A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer (NCT03319940)
  • A First In-Human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 764532 administered by repeated intravenous infusions in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3 (NCT04429087)